BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
36
Data completeness
4/8 — Partial
Priority Review
ULTOMIRIS (ravulizumab) by AstraZeneca is complement inhibitors [moa]. First approved in 2018.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ULTOMIRIS (ravulizumab) is a monoclonal antibody complement inhibitor developed by AstraZeneca and approved by the FDA on December 21, 2018. It works by inhibiting the complement cascade, a key pathway in the immune system involved in cell destruction and inflammation. The product is administered via injection and represents an advance in complement-targeted therapy for complement-mediated diseases.
$0.2BPart D
Mechanism of Action
Complement Inhibitors
Pharmacologic Class:
Complement Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (36)
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Started Aug 2026
21 enrolled
NMOSDNeuromyelitis Optica Spectrum Disorder
Ravulizumab Outcomes in Polish Patients With aHUS
Started Apr 2026
80 enrolled
Atypical Hemolytic Uremic Syndrome
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
Started Mar 2026
75 enrolled
Generalized Myasthenia GravisgMG
Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab
Started Jan 2026
24 enrolled
Myasthenia Gravis Generalised
Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
Started Dec 2025
20 enrolled
aHUSAtypical Hemolytic Uremic Syndrome
Worked on ULTOMIRIS at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.